The benchtop DNA printer developer DNA Script has expanded upon its most recent venture capital funding round, tacking on an additional $35 million for a grand total of $200 million. The financing will help promote the launch of its new systems.
In late October 2021, the company tallied up $165 million in a series C round co-led by Coatue Management and Catalio Capital Management. Other new investors in that nine-digit fundraising included Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital and Moore Strategic Ventures.
Now with a second tranche of investors, DNA Script added T. Rowe Price, Baillie Gifford, HealthCor Management, eureKARE and Irving Investors.